Application of Quillaja saponaria extracts as oral adjuvants for plant-made vaccines

Bibliography

• CURTISS RI, CARDINEAU GA: Oral immunization by transgenic plants. In: World Patent Application. WIPO: Washington University (1990).
   Google Scholar
• STREATFIELD SJ, JILKA JM, HOOD EE et al.: Plant-based vaccines: unique advantages. Vaccine (2001) 19(17-19):2742–2748.
   PubMed Web of Science ®Google Scholar
• •Review of PMV development and applications.
   Google Scholar
• WALMSLEY AM, ARNTZEN CJ: Plant cell factories and mucosal vaccines. Carr.Opin. Biotechnol (2003) 14(2):145–150.
   PubMed Web of Science ®Google Scholar
• •Review of PMV development and applications.
   Google Scholar
• STREATFIELD SJ, HOWARD JA: Plant-based vaccines. Int. .1. Parasitol (2003) 33(5–6):479–493.
   Google Scholar
• HAQ TA, MASON HS, CLEMENTS JD, ARNTZEN CJ: Oral immunization with a recombinant bacterial antigen produced in
   Google Scholar
• YU J, LANGRIDGE WH: A plant-based multicomponent vaccine protects mice from enteric diseases. Nat. Biotechnol (2001) 19(6):548–552.
   PubMed Web of Science ®Google Scholar
• WALMSLEY AM, KIRK DD, MASON HS: Passive immunization of mice pups through oral immunization of dams with a plant-derived vaccine. Inununol. Lett. (2003) 86(1):71–76.
   PubMed Web of Science ®Google Scholar
• WALMSLEY AM, ALVAREZ ML, JIN Y et al.: Expression of the B subunit of Escherichia cob heat-labile enterotoxin as a fusion protein in transgenic tomato. Plant Cell Rep. (2003) 21(10):1020–1026.
   PubMed Web of Science ®Google Scholar
• RIGANO MM, ALVAREZ ML, PINKHASOV J et al.: Production of a fusion protein consisting of the enterotoxigenic Escherichia cob heat-labile toxin B subunit and a tuberculosis antigen in Arabidopsis thaliana. Plant Cell Rep. (2004) 22(7):502–508.
   PubMed Web of Science ®Google Scholar
• WEBB SR, MILLER TJ, FANTON M et al: Immune response in chickens following the oral adminsitration of plant- expressed heat labile toxin. NFID Sixth Annual Conference on Vaccine Research. Arlington, VA, USA (5 — 7 May 2003).
   Google Scholar
• DEL GIUDICE G: Mucosal vaccines: the use of LT mutants as safe adjuvants. Third meeting on novel adjuvants currently in or close to clinical testing, World Health Organization. Annecy, France (7 — 9 January 2002).
   Google Scholar
• BRENNAN FR, HAMILTON WDO: Food grade saponins as oral adjuvants. In: World Intellectual Property Organization. The Dow Chemical Company (2001).
   Google Scholar
• •First predinical studies and discussion of utility for food-grade quillaja saponins.
   Google Scholar
• WALMSLEY AM, ROWLAND L, KIRK DD, MILLER TJ, MASON HS: Efficacy of an edible, plant-derived immunocontraceptive vaccine in mice and voles. NFID Sixth Annual Conference on Vaccine Research. Arlington, VA, USA (5 —7 May 2003).
   Google Scholar
• KIRK DD, VONHOF WM, EIBNER J, MASON HS, ZHANG X: Model production of a potent plant-made vaccine. NFID Sixth Annual Conference on Vaccine
   Google Scholar
• ••Research. Arlington, VA, USA (5–7 May 2003).
   Google Scholar
• •First proposal of human clinical vaccine trial with food-grade quillaja extract.
   Google Scholar
• TACKET CO, MASON HS, LOSONSKY G et al.: Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat. Med. (1998) 4:607–609.
   PubMed Web of Science ®Google Scholar
• TACKET CO, CLEMENTS JD, WASSERMAN SS, STREATFIELD SJ: Immunogenicity of a recombinant bacterial antigen delivered in transgenic corn. NFID Sixth Annual Conference on Vaccine Research. Arlington, VA, USA (May 5–7 2003).
   Google Scholar
• TACKET CO, MASON HS, LOSONSKY G et al.: Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. Infect. Dis. (2000) 182(1):302–305.
   Google Scholar
• THANAVALA Y, MAHONEY M, PAL S et al.: Immunogenicity in humans of an edible vaccine for Hepatitis B. (2004) (In Press).
   Google Scholar
• ENGERS H, KIENY MP, MALHOTRA P, PINK JR: Third meeting on Novel Adjuvants Currently in or Close to Clinical Testing World Health Organization-Organisation Mondiale de la Sante, Fondation Merieux, Annecy, France, 7-9 January 2002. Vaccine (2003) 21(25-26):3503–3524.
   PubMedGoogle Scholar
• •Review of adjuvants used at present in vaccine predinical and clinical testing.
   Google Scholar
• PINK JR, KIENY MP: 4th Meeting on novel adjuvants currently in/close to human clinical testing World Health Organization-Organization Mondiale de la Sante Fondation Merieux, France, 23–25 June 2003. Vaccine (2004) (In Press).
   Google Scholar
• •Update on adjuvants used at present in vaccine predinical and clinical testing.
   Google Scholar
• CAMPBELL JB, MAHARAJ I, ROITH J: Vaccine formulations for oral immunization of laboratory animals and wildlife against rabies. In: Rabies in the Tropics. Kwert E, Merieux C, Koprowski H, Bogel K (Eds), Springer Verlag, New York, NY, USA (1985):285.
   Google Scholar
• •First proposal of oral immunisation with quillaja saponins.
   Google Scholar
• MAHARAJ I, FROH KJ, CAMPBELL JB: Immune responses of mice to inactivated rabies vaccine administered orally: potentiation by Quillaja saponin. Can. Microbiol (1986) 32(5):414–420.
   PubMed Web of Science ®Google Scholar
• ••First report of efficacy of quillaja saponinsas an oral adjuvant.
   Google Scholar
• ESPINET RG: Nouveau vaccine antiaphteux a complexe glucoviral. Cac. Vet. (1951) 13:268.
   Google Scholar
• EDELMAN R: An update on vaccine adjuvants in clinical trial. AIDS Res. Hum. Retroviruses (1992) 8(8):1409–1411.
   PubMed Web of Science ®Google Scholar
• KENSIL CR: Saponins as vaccine adjuvants. Grit. Rev. Ther. Drug Carrier Syst. (1996) 13(1-2):1–55.
   PubMed Web of Science ®Google Scholar
• ••Thorough review of the use anddevelopment of quillaja saponins as adjuvants.
   Google Scholar
• SAN MARTIN R, BRIONES R: Industrial uses and sustainable supply of Quilleja saponaria (Rosaceae) saponins. Economic Botany (1999) 53:302–311.
   Web of Science ®Google Scholar
• KENSIL CR, PATEL U, LENNICK M, MARCIANI D: Separation and characterization of saponins with adjuvant activity from Quilleja saponaria Molina cortex.' Immunol (1991) 146(2):431–437.
   Web of Science ®Google Scholar
• SJoLANDER A, COX JC: Uptake and adjuvant activity of orally delivered saponin and ISCOMTM vaccines. Adv. Drug Deliv. Rev (1998) 34:321–338.
   PubMed Web of Science ®Google Scholar
• VOGEL FR, POWELL MF: A compendium of vaccine adjuvants and excipients. Pharm. Biotechnol (1995) 6:141–228.
   PubMedGoogle Scholar
• MOWAT AM, DONACHIE AM, JAGEWALL S et al: DTAl-DD-Immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effect with nanogram doses of antigen. I Immunol (2001) 167:3398–3405.
   PubMed Web of Science ®Google Scholar
• EVANS TG, MCELRATH MJ, MATTHEWS T et al.: QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine (2001) 19(15-16):2080–2091.
   PubMed Web of Science ®Google Scholar
• WAITE DC, JACOBSON EW, ENNIS FA et al.: Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine (2001) 19(28-29):3957–3967.
   PubMed Web of Science ®Google Scholar
• MOWAT AM, SMITH RE, DONACHIE AM et al.: Oral vaccination with immune stimulating complexes. Immunol Lett. (1999) 65(1-2):133–140.
   PubMed Web of Science ®Google Scholar
• FURRIE E, SMITH RE, TURNER MW, STROBEL S, MOWAT AM: Induction of local innate immune responses and modulation of antigen uptake as mechanisms underlying the mucosal adjuvant properties of immune stimulating complexes (ISCOMS). Vaccine (2002) 20(17-18):2254–2262.
   PubMed Web of Science ®Google Scholar
• DRANE D, PEARSE M: The ISCOM technology: further developments. Third meeting on novel adjuvants currently M or close to clinical testing, World Health Organization. Annecy, France (2003).
   Google Scholar
• ROBSON NC, BEACOCK-SHARP H, DONACHIE AM, MOWAT AM: The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes. Immunology (2003) 110(1):95–104.
   PubMed Web of Science ®Google Scholar
• ROBSON NC, BEACOCK-SHARP H, DONACHIE AM, MOWAT AM: Dendritic cell maturation enhances CD8[ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading. Immunology (2003) 109(3):374–383.
   PubMed Web of Science ®Google Scholar
• CHAVALI SR, FRANCIS T, CAMPBELL JB: An in vitro study of immunomodulatory effects of some saponins. Int. I Immunopharmacol (1987) 9(6):675–683.
   PubMed Web of Science ®Google Scholar
• CHAVALI SR, CAMPBELL JB: Adjuvant effects of orally administered saponins on humoral and cellular immune responses in mice. Immunobiology (1987) 174(3):347–359.
   PubMed Web of Science ®Google Scholar
• LIVINGSTON PO, ADLURI S, HELLING F et al.: Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine (1994) 12(14):1275–1280.
   PubMed Web of Science ®Google Scholar
• DALSGAARD: A study of the isolation and characterization of the saponin Quil A. Evaluation of its adjuvant activity, with a special reference to the application in the vaccination of cattle against foot-and-mouth disease. Acta Vet. Scand. Sapp]. (1978) (69):7–40.
   Google Scholar
• KERSTEN GF, CROMMELIN DJ: Liposomes and ISCOMs. Vaccine (2003) 21(9-10):915–920.
   PubMed Web of Science ®Google Scholar
• COX JC, SJOLANDER A, BARR IG: ISCOMs and other saponin based adjuvants. Adv. Drug Deify. Rev (1998) 32(3):247–271.
   PubMed Web of Science ®Google Scholar
• LYCKE N: From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTAl-DD/IS C OM. Cell Microbiol (2004) 6(1):23–32.
   PubMed Web of Science ®Google Scholar
• BOYAKA PN, MARINARO M, JACKSON RI et al: Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity. J. Immunol (2001) 166(4):2283–2290.
   PubMed Web of Science ®Google Scholar
• •Only peer-reviewed report describing use of QS-21 as an oral adjuvant.
   Google Scholar
• SIDHU GS, OAKENFULL DG: A mechanism for the hypocholesterolaemic activity of saponins. Br: J. Nutr. (1986) 55(3):643–649.
   PubMed Web of Science ®Google Scholar
• ALVAREZ JR, TORRES-PINEDO R: Interactions of soybean lectin, soyasaponins, and glycinin with rabbit jejunal mucosa in vitro. Pediatr. Res. (1982) 16(9):728–731.
   PubMed Web of Science ®Google Scholar
• NAKADA Y, AWATA N, NAKAMICHI C, SUGIMOTO I: The effect of additives on the oral mucosal absorption of human calcitonin in rats. Phannacobiodyn. (1988) 11(6):395–401.
   PubMedGoogle Scholar
• SAN MARTIN R, BRIONES R: Quality control of commercial quillaja (Quilleja saponaria Molina) extracts by reverse phase HPLC. Sci. Food Agric. (2000) 80:2063–2068.
   Web of Science ®Google Scholar
• BACK H: Beitrage zur kenntinis der ausscheidung der saponine durch den kot. Biochem. Z (1917) 86:223.
   Google Scholar
• FIEGER J: Uber die ausscheidung von saponinen durch den ham and ihre wirkung aouf das blut nach innerlicher darreichung. Biochem. Z (1918) 86:244.
   Google Scholar
• GAUNT IF, GRASSO P, GANGOLLI SD: Short-term toxicity of quillaja extracts in rats. Food Cosmet. Toxicol (1974) 12:641–650.
   PubMedGoogle Scholar
• GEORGE Al: Legal status and toxicity ofsaponins. Food Cosmet. Toxicol (1965) 3:85–91.
   PubMedGoogle Scholar
• NEWMAN HA, KUMMEROW FA, SCOTT HM: Dietary saponin, a factor which may reduce liver and serum cholesterol levels. Poultry Sci. (1958) 37(1):42.
   Web of Science ®Google Scholar
• VOGEL G, MAREK M-L: Zur pharmakologie einiger saponine. Arzneimittel-Forsch (1962) 12:815–825.
   PubMed Web of Science ®Google Scholar
• ERBRING H, VOGEL G: Die bedeutung physikalischer zustandsanderungen fur die enterale resorption schwer resorierbarer saponine. Arzneimittel-Forsch (1963) 13:467.
   Web of Science ®Google Scholar
• GESTETNER B, BIRK Y, TENCER Y: Soybean saponins. Fate of ingested soybean saponins and the physiological aspect of their hemolytic activity. I Agric. Food Chem. (1968) 16:1031.
   Google Scholar
• PETERSON DW: Effect of sterols on the growth of chicks fed high alfalfa diets or a diet containing Quillaja saponin. I Nutr. (1950) 42:597–607.
   PubMed Web of Science ®Google Scholar
• COULSON CB, EVANS RA: The effect of saponin, sterols and linoleic acid on the weight increase of growing rats. Br. Nutr. (1960) 14:121–134.
   PubMed Web of Science ®Google Scholar
• BRUNE H, GUNTHER K: Zur frage der wirksamkeit der saponine als antivitamin D. Z Ernahrungswiss (1961) 2:45.
   Google Scholar
• EFIMOVA TG, PIVNENKO GP, KOUTSEVICH VA, SIKOVA NY: The action of soapbark tree Quilleja saponaria saponins on blood pressure and cholesterol content in animals. Farm. Zh. (Kiev) (1966) 21:45–49.
   PubMedGoogle Scholar
• OSER BL: An evaluation of Yucca mohavensis as a source of food grade saponin. Food Cosmet. Toxicol (1966) 4(1):57–61.
   PubMedGoogle Scholar
• PHILLIPS JC, BUTTERWORTH KR, GAUNT IF, EVANS JG, GRASSO P: Long-term toxicity study of quillaia extract in mice. Food Cosmet. Toxicol (1979) 17(1):23–27.
   PubMedGoogle Scholar
• DRAKE JJ, BUTTERWORTH KR, GAUNT IF et al.: Long-term toxicity study quillaia extract in rats. Food Chem. Toxicol (1982) 20(1):15–23.
   PubMed Web of Science ®Google Scholar